Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Return on Sales (2020 - 2023)

Candel Therapeutics' Return on Sales history spans 4 years, with the latest figure at 15.71% for Q4 2023.

  • For Q4 2023, Return on Sales rose 26410.0% year-over-year to 15.71%; the TTM value through Dec 2023 reached 14.99%, up 29403.0%, while the annual FY2024 figure was 14.45%, 2944.0% down from the prior year.
  • Return on Sales for Q4 2023 was 15.71% at Candel Therapeutics, up from 13.49% in the prior quarter.
  • Across five years, Return on Sales topped out at 15.71% in Q4 2023 and bottomed at 1291.67% in Q4 2021.
  • The 4-year median for Return on Sales is 196.03% (2020), against an average of 240.42%.
  • The largest annual shift saw Return on Sales plummeted -109563bps in 2021 before it surged 104328bps in 2022.
  • A 4-year view of Return on Sales shows it stood at 196.03% in 2020, then tumbled by -559bps to 1291.67% in 2021, then soared by 81bps to 248.39% in 2022, then soared by 106bps to 15.71% in 2023.
  • Per Business Quant, the three most recent readings for CADL's Return on Sales are 15.71% (Q4 2023), 13.49% (Q3 2023), and 15.17% (Q2 2023).